CD4+CD25+Foxp3+T调节细胞与小鼠异基因造血干细胞移植GVHD相关性研究

目的探讨CD4 CD25 foxp3 调节性T细胞与小鼠GVHD发生的相关性。方法取8～10周龄的SPF级CB6F1小鼠(H-2b/d,♀)30只,随机分为正常对照组、同基因移植组和GVHD组,每组10只,正常对照组不接受照射和移植,同基因移植组小鼠照射后接受CB6F1小鼠骨髓细胞(1×107)和脾细胞(3×107),GVHD组小鼠照射后接受C57BL/6(H-2b,♂)小鼠骨髓细胞(1×107)和脾细胞(3×107)。在发生GVHD的时间点检测3组小鼠脾细胞CD4 CD25 T细胞和foxp3 mRNA的表达。结果正常对照组、同基因移植组和GVHD组小鼠脾细胞中CD4 CD25 T细胞的比例分别为(8.47±1.03)%、(15.40±0.80)%和(24.03±0.85)%,均有显著性差异(P<0.01)。GVHD组小鼠脾细胞foxp3 mRNA的表达水平明显低于正常对照组和同基因移植组,有显著性差异(P<0.001)。结论CD4 CD25 foxp3 调节性T细胞与小鼠GVHD发生呈负相关,发生GVHD时小鼠脾细胞中CD4 CD25 foxp3 调节性T细胞明显减低。     

肝复灵胶囊的研制

目的：介绍肝复灵胶囊的研制和质量控制方法。方法：用高效液相法测定了肝复灵胶囊中芍药苷的含量。结果：平均回收率为99.13％．RSD为1．4％(n=6)。结论：研制方法及质检方法可行，可靠。     

一株新的急性髓系白血病细胞系SH-2的建立及其鉴定

Objective To establish and characterize a novel human myeloid leukemia cell line SH-2. Methods Bone marrow mononuclear cells(BMMNC) isolated from a AML-M2 patient, who failed to ob-tain complete remission after chemotherapy and allogenic bone marrow transplantation were passed in a long term IMDM culture medium supplemented with 20% fetal calf serum. Stromal cells were retained and rh-IL-3was added in the culture system. A new human myeloid leukemia cell line SH-2 was successfully established with a cytogeuetic characteristics of a loss of Y chromosome(- Y), a derivative chromosome 16 resulting from unbalanced translocation between chromosome 16 and 17, monosome 17, trisomy 19 and p53 alteration. Vari-ous methods were employed to characterize SH-2 cell line. Results SH-2 cells has been maintained without cytokine and stromal cells for more than 3 years without EB virus and mycoplasma contamination. SH-2 cells had the basically same morphological, immunophenotypic and cytogenetic features as the patient' s leukemia cells did, such as myeloid morphology, an immunophenotype of CD13+ , CD33+ , CD56+ , CD16/56+ and a hypodiploid karyotype of 45, X, - Y, der(16) t(16;17) (q24;q12) , - 17, + 19, which were gradually de-creased and replaced by the near-tetraploid cells with a karyotype of 73 - 102 (80), XX, - Y, - Y, del (lq31) ×2, der(16)t(16;17) (q24;q12) ×2, - 17, - 17, + 19, + 19. FISH and multiple FISH delineated all the abnormalities and revealed a loss of one p53 allele due to monosomy 17. DNA direct sequencing detec-ted a point mutation of CAG to CAT at codon 576 of exon 5 in another p53 allele. RT-PCR showed that SH-2 cells expressed apoptosis-related genes (bcl-2, Fas, GST- π and p21) rather than MDR-related genes. Short tandem repeat PCR provided powerful evidence for the derivation of SH-2 cell line from the patient' s leukemia cells. SH-2 cells had certain colony formation and tumorigenic capacities in nude and SCID mice. Conclu-sion SH-2 is a new myeloid leukemia cell line with a unique biology background, and will provide a useful tool for leukemia research.     

纯红系白血病(M6b)一例报告——附文献复习

目的 提高对纯红系白血病(M6b)生物学本质的认识.方法 报告1例纯红系白血病患者的临床和实验室检查特征、治疗经过、预后并结合文献复习讨论.结果 患者骨髓原始红细胞占0.904,免疫表型:CD71+细胞占99.5%、血型糖蛋白A(GPA)+细胞占67.4%,无干祖细胞、髓系、淋系、巨核系抗原表达,予以HAG(高三尖杉酯碱+阿糖胞苷+G-CSF)方案化疗无效,病情持续进展,多发性髓外浸润,很快死于多器官功能衰竭.结论 纯红系白血病恶性程度高,对常规化疗方案治疗无效,预后极差.     

一株新的急性髓系白血病细胞系SH-2的建立及其鉴定

Objective To establish and characterize a novel human myeloid leukemia cell line SH-2. Methods Bone marrow mononuclear cells(BMMNC) isolated from a AML-M2 patient, who failed to ob-tain complete remission after chemotherapy and allogenic bone marrow transplantation were passed in a long term IMDM culture medium supplemented with 20% fetal calf serum. Stromal cells were retained and rh-IL-3was added in the culture system. A new human myeloid leukemia cell line SH-2 was successfully established with a cytogeuetic characteristics of a loss of Y chromosome(- Y), a derivative chromosome 16 resulting from unbalanced translocation between chromosome 16 and 17, monosome 17, trisomy 19 and p53 alteration. Vari-ous methods were employed to characterize SH-2 cell line. Results SH-2 cells has been maintained without cytokine and stromal cells for more than 3 years without EB virus and mycoplasma contamination. SH-2 cells had the basically same morphological, immunophenotypic and cytogenetic features as the patient' s leukemia cells did, such as myeloid morphology, an immunophenotype of CD13+ , CD33+ , CD56+ , CD16/56+ and a hypodiploid karyotype of 45, X, - Y, der(16) t(16;17) (q24;q12) , - 17, + 19, which were gradually de-creased and replaced by the near-tetraploid cells with a karyotype of 73 - 102 (80), XX, - Y, - Y, del (lq31) ×2, der(16)t(16;17) (q24;q12) ×2, - 17, - 17, + 19, + 19. FISH and multiple FISH delineated all the abnormalities and revealed a loss of one p53 allele due to monosomy 17. DNA direct sequencing detec-ted a point mutation of CAG to CAT at codon 576 of exon 5 in another p53 allele. RT-PCR showed that SH-2 cells expressed apoptosis-related genes (bcl-2, Fas, GST- π and p21) rather than MDR-related genes. Short tandem repeat PCR provided powerful evidence for the derivation of SH-2 cell line from the patient' s leukemia cells. SH-2 cells had certain colony formation and tumorigenic capacities in nude and SCID mice. Conclu-sion SH-2 is a new myeloid leukemia cell line with a unique biology background, and will provide a useful tool for leukemia research.     

造血干细胞移植术后巨细胞病毒感染状况——单中心七年临床研究

人类巨细胞病毒(HCMV)属于β疱疹病毒亚科,也称疱疹病毒5型.CMV感染遍布全球,不同国家及地区的资料显示,人群中的感染率高达40%～100%,我国则在90%以上.和所有疱疹病毒一样,人一经感染,除少数出现临床症状外,大多呈隐性感染.     

自然杀伤T淋巴细胞与移植物抗宿主病的研究进展

移植物抗宿主病(GVHD)是目前导致异基因造血干细胞移植(allo-HSCT)失败和受者死亡的重要因素,与移植物抗白血病效应(GVL)和受者的生活质量密切相关.GVHD是由供者移植物巾的T淋巴细胞识别宿主抗原引起的免疫反应所导致受者多器官损伤,涉及各种免疫活性细胞、细胞因子和炎症因子[1].     

异基因造血干细胞移植治疗T淋巴母细胞淋巴瘤/白血病1例并文献复习

目的:探讨T淋巴母细胞淋巴瘤/白血病的临床诊断及治疗方法。方法:报告1例T淋巴母细胞淋巴瘤/白血病的病例,并复习相关文献。结果:患者通过手术病理及骨髓相关检查确诊T淋巴母细胞淋巴瘤/白血病,联合化疗后行母供子半相合造血干细胞移植术,术后1年患者出现复发趋势,予供体淋巴细胞输注后本病再次处于缓解状态,目前患者病情稳定。结论:T淋巴母细胞淋巴瘤/白血病是高度恶性淋巴瘤,一旦进展为白血病阶段,预后恶劣,生存期短,造血干细胞移植联合供体淋巴细胞输注是治疗本病延长生存期的一种有效的方法。     

血液病化疗后致败血症68例临床分析

目的:研究血液病患者化疗后发生败血症的特点、原因、预后及治疗。方法:回顾性分析68例化疗后发生败血症的血液病患者的病原学特点、感染部位、发病相关因素及转归。结果:化疗后败血症患者主要病原菌为大肠埃希菌(26.5%),铜绿假单胞菌(17.6%),肺炎克雷伯菌(10.3%)。革蓝阴性菌对亚胺培南及丁胺卡那最敏感,革蓝阳性菌对万古霉素及替考拉宁最敏感。呼吸道感染最多见。中性粒细胞计数≤0.1×109/L及粒细胞缺乏持续时间≥7天的患者败血症发生率显著升高。结论:大肠埃希菌,铜绿假单胞菌,草绿色链球菌及葡萄球菌为血液病患者化疗后败血症的主要致病菌,败血症的发生与中性粒细胞计数及粒缺维持时间相关。需重视对患者的早期防治,强力抗感染治疗,联合粒细胞集落刺激因子应用可减少重症感染发生。     

非T细胞去除单倍体造血干细胞移植治疗T淋巴母细胞性淋巴瘤的初步临床研究

 目的　探讨非T细胞去除单倍体造血干细胞移植（haplo-HSCT）治疗T淋巴母细胞性淋巴瘤（T-LL）的疗效。方法　3例确诊的T-LL患者获得缓解后接受了粒细胞集落刺激因子（G-CSF）动员后的非T细胞去除的单倍体亲缘供体的骨髓干细胞输注。其中2例患者预处理采用包含环磷酰胺（CTX）、全身照射（TBI）和阿糖胞苷（Ara-C）的清髓性方案,另1例患者采用包含CTX和白消安（BU）、Ara-C的清髓性方案;3例患者都采用了包含兔抗人胸腺细胞球蛋白（ATG）的加强的急性移植物抗宿主病预防方案。结果　所有患者均获得快速完全的造血重建,中性粒细胞和血小板中位恢复时间分别为12 d和13 d。3例患者中位随访24个月（9～75个月）,均无瘤生存。结论　非T细胞去除haplo-HSCT治疗T-LL的相关不良反应可以耐受,患者可能获得长期生存。